Chiasma ups IPO price

Chiasma, a biotech developing oral therapies for orphan diseases only treated by injections, raised $102 million by offering 6.4 million shares (100% primary) at $16, above the $13-$15 range. Chiasma sold 1.0 million more shares than originally planned.

At 16 dollar Chisma will have a mcap of $450 million.